To access all features of this site, you must enable Javascript. Here are the instructions for enabling Javascript in your web browser.
The François Jacob Institute of Biology brings together five departments and three services
The last two years in scientific news
An innovative method uniting 3D histological reconstructions and voxel-based analysis developed by a CEA/CNRS team at MIRCen enables the automated identification of cerebral zones were proteins characteristic of Alzheimer's disease develop.
A partnership between the François Jacob Institute of Biology/CEA, The Frédéric Joliot Institute for Life Sciences/CEA and CellTechs (a Sup'Biotech lab) has led to a new approach for modeling Alzheimer's disease in vitro.
The propagation of tau protein aggregates in the brain contributes to the progression of Alzheimer’s disease. Researchers at the Neurodegenerative Diseases Laboratory: mechanisms, therapies, imaging (CNRS/CEA/Université Paris-Sud, MIRCen), working in collaboration with the Ecole Normale Supérieure, Sorbonne University and Inserm, have just identified the targets of these aggregates.
A research team from MIRCen has shown that the relative size of the neocortex is constant across all primates, whereas the volume of white matter varies considerably according to the type of primate.
A Genoscope team has reconstructed compete plant chromosomes by combining DNA long-read sequencing and optical mapping technologies.
Researchers from MIRCen have shown that inhibiting reactive astrocytes is beneficial for certain characteristics of Alzheimer's disease. Their results could lead to novel therapies that act upon astrocytes to improve neuron function.
The workshop on Medical Genomics aims at uniting the genomic community over two days and will include talks from GENMED partners who will present their latest results in human disease genomics. In addition, internationally renowned speakers will be invited to give general presentations covering broader and innovative topics in the field of “omic” research.
The CEA held its Symposium for Functional Genomics on 4–5 April 2018 at the Fontenay-aux-Roses site.
Theranexus, a CEA-born biopharmaceutical company, signs a three-year research partnership agreement with the Collège de France.
NeurATRIS lance un appel à projets pour initier des projets collaboratifs entre les membres de NeurATRIS, les laboratoires académiques et les sociétés de biotechnologies. A la clé, un financement à hauteur de 50K€.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.